nach oben

Current Breast Cancer Reports

Erschienen in:

13.07.2019 | Risk and Prevention (ME Wood, Section Editor)

Breast Atypia as a Biomarker of Risk

verfasst von: Amy C. Degnim

Erschienen in: Current Breast Cancer Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Provide a summary of available evidence on breast atypia as a biomarker of risk.

Recent Findings

With an increase in independent studies on atypical hyperplasia (AH), knowledge has advanced recently regarding its subsequent associated breast cancer risk. For women with AH, absolute risk can be estimated generally as ~ 1% per year, and a greater extent of disease appears to further increase risk. Although both breasts are at increased risk, the risk is higher for the ipsilateral breast. In women with AH, a family history of breast cancer does not confer significantly increased risk. Risk is similar for atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), with some reports suggesting mildly higher risk for ALH. Prevention medications reduce breast cancer risk by ~ 70% in AH.

Summary

Women with AH should be counseled on their increased risk and the option of prevention medication.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51. https://doi.org/10.1056/NEJM198501173120303.CrossRefPubMed

Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol. 1992;23(10):1095–7.CrossRefPubMed

Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol. 1988;128(3):467–77.CrossRefPubMed

London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267(7):941–4.CrossRefPubMed

Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229–37. https://doi.org/10.1056/NEJMoa044383.CrossRefPubMed

Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014;7(2):211–7. https://doi.org/10.1158/1940-6207.CAPR-13-0222.CrossRef

Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627–33. https://doi.org/10.1007/s10549-012-2318-8.CrossRefPubMed

• Donaldson AR, McCarthy C, Goraya S, Pederson HJ, Sturgis CD, Grobmyer SR, et al. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. Cancer. 2018;124(3):459–65. https://doi.org/10.1002/cncr.31061 This paper reports breast cancer risk in a modern cohort of women with high-risk histologic findings that were diagnosed percutaneously, confirming breast cancer risk similar to women with high-risk lesions diagnosed by surgical excision. CrossRefPubMed

• Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 2017;3(1):36–41. https://doi.org/10.1001/jamaoncol.2016.3022 In this multicenter screening mammography cohort, risk of invasive breast cancer in women with ADH appears lower than estimates from cohorts of women undergoing breast biopsy. CrossRefPubMedPubMedCentral

10.

Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26(33):5374–9. https://doi.org/10.1200/JCO.2007.14.8833.CrossRefPubMedPubMedCentral

11.

Boughey JC, Hartmann LC, Anderson SS, Degnim AC, Vierkant RA, Reynolds CA, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28(22):3591–6. https://doi.org/10.1200/JCO.2010.28.0784.CrossRefPubMedPubMedCentral

12.

Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.CrossRefPubMed

13.

Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomark Prev. 1997;6(5):297–301.

14.

Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses’ Health Study. Cancer. 2007;109(2):180–7. https://doi.org/10.1002/cncr.22408.CrossRefPubMed

15.

•• Collins LC, Aroner SA, Connolly JL, Colditz GA, Schnitt SJ, Tamimi RM. Breast cancer risk by extent and type of atypical hyperplasia: an update from the Nurses’ Health Studies. Cancer. 2016;122(4):515–20. https://doi.org/10.1002/cncr.29775 In the Nurses’ Health Study, there was no significant association of the extent of atypical hyperplasia of with subsequent breast cancer risk. CrossRefPubMed

16.

Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(7):1053–60. https://doi.org/10.1007/s00432-011-0979-z.CrossRefPubMedPubMedCentral

17.

Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses’ Health Study. Cancer. 2006;107(6):1240–7. https://doi.org/10.1002/cncr.22136.CrossRefPubMed

18.

Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med. 2015;372(1):78–89. https://doi.org/10.1056/NEJMsr1407164.CrossRefPubMedPubMedCentral

19.

Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361(9352):125–9. https://doi.org/10.1016/S0140-6736(03)12230-1.CrossRefPubMed

20.

Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.CrossRefPubMed

21.

Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671–7. https://doi.org/10.1200/JCO.2006.09.0217.CrossRefPubMed

22.

Degnim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD, et al. Breast cancer risk by the extent and type of atypical hyperplasia. Cancer. 2016;122(19):3087–8. https://doi.org/10.1002/cncr.30151.CrossRefPubMed

23.

•• Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, et al. Model for predicting breast cancer risk in women with atypical hyperplasia. J Clin Oncol. 2018;36(18):1840–6. https://doi.org/10.1200/JCO.2017.75.9480 This is a new breast cancer risk prediction model specifically designed for women with atypical hyperplasia that was developed in the Mayo Clinic Benign Breast Disease Cohort and validated in the Nashville Breast Cohort. CrossRefPubMedPubMedCentral

24.

King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52. https://doi.org/10.1200/JCO.2015.61.4743.CrossRefPubMedPubMedCentral

25.

•• Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, et al. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer. 2016;122(19):2971–8. https://doi.org/10.1002/cncr.30153 In the Nashville and Mayo Clinic Benign Breast Disease Cohorts, the number of foci of atypical hyperplasia is significantly associated with subsequent breast cancer risk, with increasing risk observed in women with more foci of atypia. CrossRefPubMed

26.

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017;35(10):1061–9. https://doi.org/10.1200/JCO.2016.69.4406.CrossRefPubMedPubMedCentral

27.

Santisteban M, Reynolds C, Barr Fritcher EG, Frost MH, Vierkant RA, Anderson SS, et al. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat. 2010;121(2):431–7. https://doi.org/10.1007/s10549-009-0534-7.CrossRefPubMed

28.

Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, et al. ERbeta expression and breast cancer risk prediction for women with atypias. Cancer Prev Res (Phila). 2015;8(11):1084–92. https://doi.org/10.1158/1940-6207.CAPR-15-0198.CrossRef

29.

Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005;65(21):10113–9. https://doi.org/10.1158/0008-5472.CAN-05-1524.CrossRefPubMed

30.

Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, et al. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst. 2008;100(6):421–7. https://doi.org/10.1093/jnci/djn036.CrossRefPubMed

31.

Nasir A, Chen DT, Gruidl M, Henderson-Jackson EB, Venkataramu C, McCarthy SM, et al. Novel molecular markers of malignancy in histologically normal and benign breast. Pathol Res Int. 2011;2011:1–18. https://doi.org/10.4061/2011/489064.CrossRef

32.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974–9. https://doi.org/10.1073/pnas.0931261100.CrossRefPubMedPubMedCentral

Titel: Breast Atypia as a Biomarker of Risk
verfasst von: Amy C. Degnim
Publikationsdatum: 13.07.2019
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports / Ausgabe 3/2019
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-019-00315-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Breast Atypia as a Biomarker of Risk

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Treatment in Resource Constrained Countries: a Zimbabwean Perspective

Breast Cancer Management Among Refugees and Forcibly Displaced Populations: a Call to Action

Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and Kenya

Mammographic Density: Intersection of Advocacy, Science, and Clinical Practice

Late Presentation of Breast Cancer in Lower- and Middle-Income Countries

Screening Modalities for Women at Intermediate and High Risk for Breast Cancer

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie